贝达喹啉在治疗耐多药结核病方面与氟喹诺酮类药物一样有效吗？ - Suppr | 超能文献

相似文献

1

Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?贝达喹啉在治疗耐多药结核病方面与氟喹诺酮类药物一样有效吗？

Eur Respir J. 2016 Aug;48(2):582-5. doi: 10.1183/13993003.00411-2016. Epub 2016 Jun 23.

2

Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: How Much Better Are They?贝达喹啉及其他用于耐氟喹诺酮类多药耐药结核病的 repurposed 药物：它们的效果究竟好多少？（注：“repurposed drugs”直译为“重新利用的药物”，这里可理解为“其他有新用途的药物”，但在专业语境下可能有更准确的医学术语对应，因未提供更多背景信息暂这样译）

Am J Respir Crit Care Med. 2018 Nov 1;198(9):1228-1231. doi: 10.1164/rccm.201801-0019LE.

3

Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.在德国，将贝达喹啉纳入耐多药/广泛耐药结核病治疗方案的成本效益分析。

Eur Respir J. 2015 Dec;46(6):1826-9. doi: 10.1183/13993003.00811-2015. Epub 2015 Oct 22.

4

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis.贝达喹啉可作为氟喹诺酮类药物耐药利福平耐药结核病标准化治疗方案中的核心药物。

Eur Respir J. 2022 Mar 24;59(3). doi: 10.1183/13993003.02124-2021. Print 2022 Mar.

5

The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report.使用贝达喹啉治疗耐多药结核病和终末期肾病患者：一例报告。

Int J Infect Dis. 2018 Nov;76:88-90. doi: 10.1016/j.ijid.2018.09.009. Epub 2018 Sep 19.

6

Multidrug-resistant tuberculosis and bedaquiline.耐多药结核病与贝达喹啉

N Engl J Med. 2014 Dec 18;371(25):2435-6. doi: 10.1056/NEJMc1412235.

7

Multidrug-resistant tuberculosis and bedaquiline.耐多药结核病与贝达喹啉

N Engl J Med. 2014 Dec 18;371(25):2436. doi: 10.1056/NEJMc1412235.

8

Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea.使用贝达喹啉和地拉曼尼联合治疗耐氟喹诺酮类多药耐药结核病：韩国一项全国性队列研究

Eur Respir J. 2021 Mar 4;57(3). doi: 10.1183/13993003.03026-2020. Print 2021 Mar.

9

Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline.对抗耐药结核病：贝达喹啉的意外益处

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):4-5. doi: 10.5588/ijtld.16.0768.

10

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.贝达喹啉在儿童和青少年耐多药结核病中的超说明书使用。

Emerg Infect Dis. 2017 Oct;23(10):1711-3. doi: 10.3201/eid2310.170303. Epub 2017 Oct 17.

引用本文的文献

1

Lineage Distribution Using Whole-Genome Sequencing and Bedaquiline, Clofazimine, and Linezolid Phenotypic Profiles among Rifampicin-Resistant Isolates from West Java, Indonesia.利用全基因组测序以及贝达喹啉、氯法齐明和利奈唑胺表型特征对印度尼西亚西爪哇耐利福平分离株进行谱系分布研究。

Int J Microbiol. 2024 Mar 4;2024:2037961. doi: 10.1155/2024/2037961. eCollection 2024.

2

Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.修订的结核病耐药和治疗结果定义，法国，2006-2019 年。

Emerg Infect Dis. 2022 Sep;28(9):1796-1804. doi: 10.3201/eid2809.220458.

3

Handling the Hurdles on the Way to Anti-tuberculosis Drug Development.